drugset / Trial / NCT02745353

Naloxegol in Cancer Opioid-Induced Constipation

NCT02745353 ↗

Phase 2 Terminated 7 enrolled Joseph Ma AstraZeneca · collab
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to compare the effect of naloxegol versus the patient's usual care in treating opioid-induced constipation, as well as the effect on the patient's quality of life and how much pain is experienced. Also, the purpose of this study is to compare whether treatment with naloxegol versus usual care has any impact on the number of hospital or clinic visits or telephone calls to the patient's physician that are related to constipation, and to determine the patient's preference for continuing to receive naloxegol as treatment for opioid-induced constipation.

Timeline

Start
2016-05
Primary completion
2017-06-22
Completion
2017-06-22

Outcome

Outcome not reported

Stopped (Enrollment): “Couldn't enough accrue patients”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Naloxegol Unknown 25 mg —

Indications